Search the GHTC website

Global health R&D delivers for Missouri

US government investment in global health R&D has delivered

Amount
$73.6 million
to Missouri research institutions
Jobs
850+ new jobs
for Missouri
Missouri's top USG-funded global health R&D institutions

Missouri's top USG-funded global health R&D institutions

Washington University
$60.8 million
Saint Louis University
$7.4 million
University of Missouri-Kansas City
$3.6 million
University of Missouri-Columbia
$1.8 million
University of Missouri-St. Louis
$81 thousand
Missouri industry in global health R&D

Missouri industry in global health R&D

Bayer
Location(s): Kansas City
Charles River Laboratories
Location(s): O’Fallon
Mediomics
Location(s): St. Louis
Pfizer
Location(s): St. Louis
Sanofi
Location(s): St. Louis

Missouri's top areas of global health R&D by USG funding

19%
Malaria
13.5%
Tuberculosis
2.7%
Diarrheal diseases
6.2%
Salmonella infections
44.6%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
11%
Other
Bacterial pneumonia & meningitis
Cryptococcal meningitis
Ebola/viral hemorrhagic fevers
Global health R&D at work in Missouri

Researchers from Washington University School of Medicine have discovered that the Zika virus uses the process of autophagy, or cellular waste disposal—a key feature of the placental barrier—to infect the fetus. Their research also showed that an existing malaria drug, hydroxychloroquine, can protect the fetus by blocking this process. The drug is already approved for short-term use in pregnant women. Further studies are needed before it can be used for the duration of pregnancy. Counterintuitively, hydroxychloroquine blocks Zika by lowering the body’s ability to clear out invaders.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: Pan American Health Organization